Quick Answer
TScan Therapeutics, Inc. reported Operating Income Loss of -$135.81 million for the year ending 2025.
- TScan Therapeutics, Inc. showed a decrease of -0.7% in Operating Income Loss from 2024 to 2025.
- This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Operating Income Loss has declined by 417.7%.
- Historical annual values: Fiscal year 2025: -$135.81 million | Fiscal year 2024: -$134.82 million | Fiscal year 2023: -$93.46 million | Fiscal year 2022: -$66.64 million | Fiscal year 2021: -$48.64 million | Fiscal year 2020: -$26.23 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: